Last 47 quarters of trend data · Healthcare · Medical - Pharmaceuticals
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 11.76 | 2.67 | 2.93 | 11.24 | 6.30 | 72.04 | 6804.25 | — | — | — | — | — | 23.06 | — | — | — | — | — | — | — | — |
| — | -96.3% | -100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 7.55 | 4.84 | 5.68 | 5.75 | 6.91 | 5.19 | 6.77 | 4.35 | 5.87 | 4.02 | 5.42 | 7.40 | 6.16 | 7.84 | 12.53 | 15.01 | 9.00 | 12.18 | 15.76 | 30.08 | 40.78 |
| — | -6.8% | -16.1% | +32.2% | +17.7% | +29.2% | +24.8% | -41.2% | -4.7% | -48.7% | -56.7% | -50.7% | -31.6% | -35.7% | -20.4% | -50.1% | -77.9% | -76.8% | +13.4% | -48.7% | -41.3% | |
| P/B Ratio | 9.82 | 6.38 | 7.22 | 7.90 | 9.45 | 7.24 | 8.65 | 5.89 | 6.84 | 4.44 | 4.85 | 5.31 | 5.11 | 4.91 | 5.40 | 5.21 | 3.00 | 3.14 | 3.28 | 4.20 | 10.03 |
| — | -12.0% | -16.5% | +34.2% | +38.1% | +63.3% | +78.2% | +11.0% | +33.8% | -9.7% | -10.1% | +1.9% | +70.6% | +56.5% | +64.5% | +24.0% | -70.1% | -64.1% | -61.0% | -30.8% | +70.2% | |
| P/FCF | 42.85 | 13.84 | 53.38 | 65.64 | 27.52 | 34.18 | — | — | 107.40 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -59.5% | — | — | -74.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 64.20 | 19.86 | 26.40 | 36.10 | 44.91 | 51.79 | 163.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -61.7% | -83.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 84.55 | 20.62 | 26.31 | 37.47 | 61.16 | 64.26 | 257.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -67.9% | -89.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.5% | 89.8% | 89.0% | 90.5% | 86.1% | 87.5% | 85.2% | 85.8% | 83.0% | 85.1% | 83.4% | 83.3% | 87.7% | 83.9% | 81.7% | 80.7% | 80.3% | 79.2% | 78.7% | 77.3% | 77.0% |
| — | +2.6% | +4.4% | +5.5% | +3.7% | +2.8% | +2.2% | +2.9% | -5.4% | +1.5% | +2.0% | +3.3% | +9.2% | +6.0% | +3.8% | +4.3% | +4.2% | +4.4% | -16.8% | -2.1% | +0.3% | |
| Operating Margin | 8.4% | 19.1% | 16.5% | 12.4% | 11.5% | 6.7% | 1.0% | -7.0% | -12.0% | -11.5% | -34.8% | -60.5% | -17.1% | -53.5% | -82.9% | -123.3% | -113.1% | -128.6% | -144.6% | -267.2% | -224.0% |
| — | +185.3% | +1561.7% | +275.4% | +196.2% | +157.9% | +102.9% | +88.4% | +30.0% | +78.5% | +58.1% | +50.9% | +84.8% | +58.4% | +42.7% | +53.9% | +49.5% | +59.4% | -1348.3% | +44.8% | +53.7% | |
| Net Margin | 5.4% | 13.9% | 15.0% | 4.4% | 8.8% | 7.2% | 0.1% | -13.5% | -12.1% | -13.0% | -33.4% | -57.9% | 27.6% | -64.0% | -77.8% | -117.2% | -143.8% | -165.6% | -141.9% | -273.7% | -212.2% |
| — | +93.8% | +13112.5% | +133.0% | +173.0% | +155.3% | +100.3% | +76.8% | -143.9% | +79.8% | +57.1% | +50.6% | +119.2% | +61.3% | +45.2% | +57.2% | +32.2% | +48.3% | -1393.2% | +42.0% | +54.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.5% | 4.8% | 5.0% | 1.6% | 3.2% | 2.6% | 0.0% | -4.5% | -3.6% | -3.6% | -7.3% | -10.1% | 5.7% | -9.6% | -8.2% | -9.9% | -11.2% | -10.1% | -7.2% | -12.3% | -12.6% |
| — | +83.9% | +13300.5% | +134.9% | +188.6% | +172.5% | +100.5% | +55.4% | -162.6% | +62.6% | +10.7% | -2.2% | +150.9% | +5.3% | -12.7% | +20.2% | +11.0% | +19.9% | -528.7% | -6.6% | -1.2% | |
| ROA | 4.1% | 2.7% | 2.7% | 0.8% | 1.8% | 1.6% | 0.0% | -2.6% | -2.1% | -2.1% | -4.4% | -6.5% | 3.8% | -6.5% | -5.6% | -6.8% | -7.9% | -7.3% | -5.3% | -8.5% | -8.1% |
| — | +72.1% | +12474.1% | +132.5% | +185.2% | +173.4% | +100.5% | +60.2% | -154.9% | +67.6% | +22.5% | +4.5% | +148.4% | +11.2% | -7.5% | +19.8% | +2.5% | +13.2% | -551.5% | -0.1% | +9.7% | |
| ROIC | 18.6% | 20.9% | 12.8% | 9.5% | 7.8% | 3.3% | 0.4% | -3.3% | -4.9% | -4.6% | -13.4% | -22.4% | -8.6% | -21.4% | -24.5% | -30.8% | -25.6% | -18.2% | -14.3% | -16.7% | -13.4% |
| — | +536.2% | +2790.7% | +388.3% | +259.1% | +171.3% | +103.3% | +85.3% | +43.2% | +78.5% | +45.3% | +27.4% | +66.4% | -17.6% | -71.7% | -84.3% | -91.1% | -34.4% | -884.6% | -40.9% | +6.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.46 | 0.22 | 0.24 | 0.46 | 0.25 | 0.27 | 0.28 | 0.32 | 0.32 | 0.32 | 0.32 | 0.26 | 0.15 | 0.18 | 0.13 | 0.14 | 0.15 | 0.12 | 0.11 | 0.11 | 0.21 |
| — | -18.8% | -15.3% | +41.5% | -22.9% | -16.0% | -10.0% | +23.2% | +108.1% | +81.5% | +141.2% | +93.2% | +0.9% | +49.6% | +14.9% | +20.2% | -26.7% | -36.8% | -28.4% | -22.0% | +267.3% | |
| Debt / EBITDA | 3.40 | 3.13 | 3.95 | 9.05 | 5.09 | 8.31 | 22.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -62.3% | -82.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.41 | 3.40 | 3.64 | 3.41 | 2.39 | 1.95 | 1.96 | 1.80 | 1.93 | 1.98 | 2.08 | 2.32 | 3.16 | 3.13 | 3.75 | 3.55 | 4.07 | 4.54 | 5.05 | 4.76 | 3.40 |
| — | +74.6% | +85.5% | +89.1% | +23.8% | -1.5% | -5.4% | -22.4% | -38.9% | -36.8% | -44.6% | -34.5% | -22.5% | -31.0% | -25.7% | -25.5% | +19.9% | +17.5% | +9.3% | +3.2% | -55.8% | |
| Quick Ratio | 3.08 | 3.06 | 3.27 | 3.08 | 2.17 | 1.72 | 1.71 | 1.58 | 1.72 | 1.75 | 1.84 | 2.09 | 2.91 | 2.90 | 3.51 | 3.35 | 3.87 | 4.35 | 4.87 | 4.61 | 3.28 |
| — | +77.6% | +90.6% | +94.8% | +26.1% | -1.6% | -6.7% | -24.5% | -41.0% | -39.7% | -47.7% | -37.6% | -24.7% | -33.3% | -27.9% | -27.2% | +17.8% | +15.4% | +6.9% | +1.7% | -57.0% | |
| Interest Coverage | 8.16 | 8.86 | 8.88 | — | — | — | 3.98 | — | — | — | — | — | — | — | — | — | — | — | — | -127.56 | -207.32 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONC stock.
BeOne Medicines AG's current P/E is 11.8x. The average P/E over the last 4 quarters is 5.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BeOne Medicines AG's current operating margin is 8.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BeOne Medicines AG's business trajectory between earnings reports.